Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event
CONCLUSIONS: In this long-term follow-up of patients with CHD, less than 70 % used high-intensity statin therapy with only small changes over time, and only 25 % used additional treatment with ezetimibe. We identified factors associated with reduced statin adherence that may be target for interventions.PMID:38657552 | DOI:10.1016/j.atherosclerosis.2024.117550 (Source: Atherosclerosis)
Source: Atherosclerosis - April 24, 2024 Category: Cardiology Authors: Ingrid Engebretsen Christoffer Bugge Henrik St øvring Einar Husebye Elise Sverre Toril Dammen Sigrun Halvorsen John Munkhaugen Source Type: research
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
CONCLUSIONS: With a real-time, targeted, individualized EHR alert as compared with usual care, the proportion of patients with atherosclerotic cardiovascular disease with LLT intensification was numerically higher but not statistically significant. Among clinicians who did not dismiss the alert, there was a > 2-fold increase in LLT intensification. EHR alerts, coupled with strategies to reduce clinician dismissal, may help address persistent gaps in LDL-C management.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04394715, https://www.clinicaltrials.gov/ct2/show/study/NCT04394715.PMID:38634282 |...
Source: Atherosclerosis - April 18, 2024 Category: Cardiology Authors: Nimish N Shah Lama Ghazi Yu Yamamoto Sanchit Kumar Melissa Martin Michael Simonov Ralph J Riello Iii Kamil F Faridi Tariq Ahmad F Perry Wilson Nihar R Desai Source Type: research
Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study
CONCLUSION: A comparative effectiveness study of these treatments using the current approach would likely bias results due to the low number of PCSK9 mAb initiators.PMID:38629975 | DOI:10.1097/EDE.0000000000001730 (Source: Cancer Control)
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Rosa Sloot Alexander Breskin Lisandro D Colantonio Andrew G Allmon Ying Yu Swati Sakhuja Ligong Chen Paul Muntner M Alan Brookhart Nafeesa Dhalwani Source Type: research
Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk
J Clin Med. 2024 Mar 25;13(7):1894. doi: 10.3390/jcm13071894.ABSTRACTVascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis. Therefore, reducing LDL cholesterol (LDL-C) to the goals recommended by clinical practice guidelines, is essential to decrease the risk of vascular complications. Despite this, current LDL-C control is scarce, even in subjects with high and very high risk. This is mainly due to an insufficient intensification of lipid-lowering treatment. In this context, it is essential to pre...
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Jose Mar ía Mostaza Carlos Escobar Source Type: research
Familial hypercholesterolemia
Indian Heart J. 2024 Mar;76 Suppl 1:S108-S112. doi: 10.1016/j.ihj.2023.12.002. Epub 2024 Apr 8.ABSTRACTFamilial hypercholesterolemia is a common genetic disorder of autosomal inheritance associated with elevated LDL-cholesterol. It is estimated to affect 1:250 individuals in general population roughly estimated to be 5 million in India. The prevalence of FH is higher in young CAD patients (<55 years in men; <60 years in women). FH is underdiagnosed and undertreated. Screening during childhood and Cascade screening of family members of known FH patients is of utmost importance in order to prevent the burden of CAD. Ea...
Source: Indian Heart J - April 10, 2024 Category: Cardiology Authors: J P S Sawhney Kushal Madan Source Type: research
Familial hypercholesterolemia
Indian Heart J. 2024 Mar;76 Suppl 1:S108-S112. doi: 10.1016/j.ihj.2023.12.002. Epub 2024 Apr 8.ABSTRACTFamilial hypercholesterolemia is a common genetic disorder of autosomal inheritance associated with elevated LDL-cholesterol. It is estimated to affect 1:250 individuals in general population roughly estimated to be 5 million in India. The prevalence of FH is higher in young CAD patients (<55 years in men; <60 years in women). FH is underdiagnosed and undertreated. Screening during childhood and Cascade screening of family members of known FH patients is of utmost importance in order to prevent the burden of CAD. Ea...
Source: Indian Heart J - April 10, 2024 Category: Cardiology Authors: J P S Sawhney Kushal Madan Source Type: research
Familial hypercholesterolemia
Indian Heart J. 2024 Mar;76 Suppl 1:S108-S112. doi: 10.1016/j.ihj.2023.12.002. Epub 2024 Apr 8.ABSTRACTFamilial hypercholesterolemia is a common genetic disorder of autosomal inheritance associated with elevated LDL-cholesterol. It is estimated to affect 1:250 individuals in general population roughly estimated to be 5 million in India. The prevalence of FH is higher in young CAD patients (<55 years in men; <60 years in women). FH is underdiagnosed and undertreated. Screening during childhood and Cascade screening of family members of known FH patients is of utmost importance in order to prevent the burden of CAD. Ea...
Source: Indian Heart J - April 10, 2024 Category: Cardiology Authors: J P S Sawhney Kushal Madan Source Type: research
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun.ABSTRACTCumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation. For primary prevention, consideration of estimated ASCVD risk frames decision making regarding...
Source: Atherosclerosis - April 5, 2024 Category: Cardiology Authors: Omar Mhaimeed Zain A Burney Stacey L Schott Payal Kohli Francoise A Marvel Seth S Martin Source Type: research
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Am J Prev Cardiol. 2024 Mar 18;18:100649. doi: 10.1016/j.ajpc.2024.100649. eCollection 2024 Jun.ABSTRACTCumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation. For primary prevention, consideration of estimated ASCVD risk frames decision making regarding...
Source: Atherosclerosis - April 5, 2024 Category: Cardiology Authors: Omar Mhaimeed Zain A Burney Stacey L Schott Payal Kohli Francoise A Marvel Seth S Martin Source Type: research
Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis
ConclusionThis meta-analysis demonstrated that the use of low/moderate-intensity statin combination therapy significantly reduced LDL-C levels compared with high-intensity statin monotherapy, making it preferable for patients with related risks. However, further trials are encouraged to evaluate potential adverse effects associated with combined therapy. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - April 5, 2024 Category: Cardiology Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Pharmacist optimization of lipid therapy in patients with peripheral vascular disease
CONCLUSION: The addition of a pharmacist consult led to an increase in the percentage of patients discharged on a high-intensity statin and an increase in overall statin intensification.PMID:38567808 | DOI:10.1093/ajhp/zxae097 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - April 3, 2024 Category: Drugs & Pharmacology Authors: Mary-Ashlyn Tucker Andrew Meyer Michael Bitonti Megan Supple Brandon Cain Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Atherosclerosis)
Source: Atherosclerosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial
CONCLUSIONS: All doses of obicetrapib taken as an adjunct to stable statin therapy significantly lowered atherogenic lipoprotein lipid parameters, showed near complete elimination of drug by 4 weeks, and were safe and well tolerated in a Japanese population, similar to previous studies of obicetrapib conducted in predominantly Caucasian participants.PMID:38569868 | DOI:10.5551/jat.64828 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - April 3, 2024 Category: Cardiology Authors: Mariko Harada-Shiba Michael H Davdison Marc Ditmarsch Andrew Hsieh Erin Wuerdeman Douglas Kling Annie Nield Mary R Dicklin Akitaka Nakata Atsushi Sueyoshi Satoshi Kuroyanagi John J P Kastelein Source Type: research
